Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 7/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2051542 | 1.00 | KCNH2 (0.44) | KCNH2SCN3ASLC6A3SCN1ASCN4A | |
| SCHEMBL2051541 | 1.00 | KCNH2 (0.44) | KCNH2SCN3ASLC6A3SCN1ASCN4A | |
| SCHEMBL31479382 | 0.86 | KCNH2 (0.52) | KCNH2SCN3A | |
| SCHEMBL5515868 | 0.86 | KCNH2 (0.52) | KCNH2SCN3A | |
| SCHEMBL2038333 | 0.85 | KCNH2 (0.60) | KCNH2SCN3ASLC6A3SCN1ASCN4A | |
| SCHEMBL28789050 | 0.85 | KCNH2 (0.60) | KCNH2SCN3ASLC6A3SCN1ASCN4A | |
| SCHEMBL2038331 | 0.85 | KCNH2 (0.60) | KCNH2SCN3ASLC6A3SCN1ASCN4A | |
| SCHEMBL28908009 | 0.84 | KCNH2 (0.41) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL28789031 | 0.81 | KCNH2 (0.46) | KCNH2SCN3ASLC6A3SCN1ASCN4A | |
| SCHEMBL31047117 | 0.81 | KCNH2 (0.46) | KCNH2SCN3ASLC6A3SCN1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2019-07-23 | — | — | US | disclosed |
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | KCNH2 2405/4885SCN3A 1465/4885SLC6A3 1083/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | KCNH2 2405/4885SCN3A 1465/4885SLC6A3 1083/4885 |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GIPR, GPR88, GPR119 | KCNH2 1908/4885SCN3A 1888/4885SLC6A3 1271/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | KCNH2 2405/4885SCN3A 1465/4885SLC6A3 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.